نتایج جستجو برای: payers factors
تعداد نتایج: 1080329 فیلتر نتایج به سال:
The ongoing consolidation between and among hospitals and physicians tends to raise prices for health care services, which poses increasing challenges for private purchasers and payers. This article examines strategies that these purchasers and payers can pursue to combat provider leverage to increase prices. It also examines opportunities for governments to either support or constrain these st...
BACKGROUND Advances in therapies for rheumatoid arthritis (RA), particularly biologics, have transformed the treatment paradigm for RA. However, the associated costs of these therapies result in a significant economic burden on the healthcare system. As a chronic disease requiring lifelong treatment, most health plans now position RA drugs as a high-priority therapeutic category. OBJECTIVE To...
Your practice is vulnerable to business-related liabilities including billing errors and omissions, discrimination, and wrongful termination. ■ NORCAL’s Physicians Administrative Defense (PAD) coverage helps you defend against these claims whether filed by government agencies, regulatory boards or third-party payers. PAD also provides for practice interruption and legal consultation. ■ Focus on...
OBJECTIVES Delivering treat-to-target strategies in rheumatoid arthritis (RA) involves commitments from both providers and payers for healthcare. We have summarised the perspectives of payers from England, where the National Health Service (NHS) provides universal care that is without cost for patients. METHODS We reviewed the literature - including that from the NHS and National Institute fo...
BACKGROUND Buprenorphine is under-utilized in treating opioid addiction. Payers and providers both have substantial influence over the adoption and use of this medication to enhance recovery. Their views could provide insights into the barriers and facilitators in buprenorphine adoption. METHODS We conducted individual interviews with 18 Ohio county Alcohol, Drug Addiction, and Mental Health ...
BACKGROUND Recently, collaboration between regulators and payers was set up and was mainly focused on evidence generation along product clinical development. However, neither the regulatory path nor the new active substance status (NASs) was considered. Granting NASs will provide the product with 8 years of data protection and 2 years of market exclusivity during which no generic could enter th...
This paper examines the issue of prices, relative to value, for cancer drugs. The analysis focuses on the effects on manufacturer pricing incentives of insurance coverage, specifically, the effectiveness of patient cost sharing, incentives created by reimbursement rules for physician-dispensed drugs, and payer ability and incentives to negotiate discounts. For pharmacy-dispensed cancer drugs, b...
BACKGROUND Market Access Agreements (MAA) between pharmaceutical industry and health care payers have been proliferating in Europe in the last years. MAA can be simple discounts from the list price or very sophisticated schemes with inarguably high administrative burden. DISCUSSION We distinguished and defined from the health care payer perspective three kinds of MAA: Commercial Agreements (C...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید